Zoetis Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
Zoetis reported Q2 2026 flat revenue of $2.5B (down 1% organic operational) and revised full-year 2026 guidance significantly downward: revenue now $9.12–$9.32B (organic down 3%–1% vs. prior guidance of +2%–5%), and adjusted net income organic growth now (9%)–(5)% vs. prior +2%–6%. U.S. companion animal revenue fell 11% due to macro-driven price sensitivity and competitive pressure on dermatology and Simparica Trio. Adjusted diluted EPS guidance cut to $6.15–$6.25 from $6.85–$7.00. International segment grew 6% organic operational, with livestock strength offsetting U.S. companion animal decline.
Why this rating
Material guidance miss (~6% revenue cut, ~12% adj. NI cut) on company's scale ($69B market cap); reflects structural market headwinds in core companion animal business, not one-time event.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.